Visit https://www.peervoice.com/SCQ860 to view the entire programme with slides. After completing “Therapeutic Sequencing in Patients With Advanced or High Risk Hodgkin Lymphoma: Strategies in Action”, participants will be able to: Identify patient- and disease-related characteristics that might affect treatment selection for patients with Hodgkin lymphoma; Describe the rationale for evolving treatment strategies in patients with Hodgkin lymphoma; Assess the evidence for emerging treatment strategies for Hodgkin lymphoma.

Visit https://www.peervoice.com/HVG860 to view the entire programme with slides. After completing “Beyond Traditional MHT to Address Menopause Symptoms: A Shared Decision-Making Process”, participants will be able to: Outline key data and differences between traditional menopausal hormone therapy (MHT) and tissue selective estrogen complex (TSEC) to guide treatment selection for menopause symptoms.

Visit https://www.peervoice.com/QNV860 to view the entire programme with slides. After completing “Clinical Conundrums in Type 2 Diabetes: Managing Challenging Cases in Primary Care”, participants will be able to: Recognise the common barriers to add-on therapy for patients with type 2 diabetes (T2DM) in the primary care setting and consequences of undertreatment; Evaluate current clinical trial data for GLP-1 receptor agonists (RAs) in the management of patients with T2DM; Design strategies to address key barriers to optimal, evidence-based treatment algorithms for patients with T2DM.

Visit https://www.peervoice.com/NHZ860 to view the entire programme with slides. After completing “Clinical Developments in Managing Autoinflammatory Diseases”, participants will be able to: Describe the impact of the latest data and clinical evidence on therapeutic strategies for patients with autoinflammatory diseases; Identify how the clinical features and disease activity associated with autoinflammatory diseases impact patient outcomes, QOL, and treatment considerations; Propose clinical, immunologic, and practical considerations for managing and vaccinating patients with autoinflammatory diseases during the COVID-19 pandemic.

Visit https://www.peervoice.com/AMX860 to view the entire programme with slides. After completing “Acute Psychosis: When to Suspect Acute Hepatic Porphyria”, participants will be able to: Recognise acute hepatic porphyria (AHP) in patients with acute psychosis; Identify patients with psychological symptoms who should be screened for AHP; Describe the importance of a multidisciplinary team approach in the management of patients with AHP.

Visit https://www.peervoice.com/SDU860 to view the entire programme with slides. After completing “An Immune System in Double Trouble: What Is ‘Best Practice’ for Managing Patients With Lymphoproliferative Malignancies?”, participants will be able to: Describe the consequences of infectious complications on outcomes of patients with suspected secondary immunodeficiency (SID) due to a lymphoproliferative malignancy; Identify the predictive risk factors of an infectious complication occurring in patients with a lymphoproliferative malignancy that would warrant the need for supportive therapy; Apply practical strategies to monitor and manage infection risk in patients with lymphoproliferative malignancies.

Visit https://www.peervoice.com/KAN860 to view the entire programme with slides. After completing “Raising the Bar in Heart Failure Management: 2021 Congress Updates on SGLT2 Inhibitors”, participants will be able to: Explain the most recent clinical evidence for SGLT2 inhibitors for the management of patients with heart failure (HF) and associated guidelines; Evaluate how these clinical data add to previous knowledge about the management of HF; Discuss the clinical implications of the guidelines and data in the context of current HF treatment paradigms.

Visit https://www.peervoice.com/JTM860 to view the entire programme with slides. After completing “Treatment Gaps in T2DM and Obesity: Personalising Care for Better Outcomes”, participants will be able to: Describe unmet needs for patients with type 2 diabetes (T2DM) and obesity; Explain safety and efficacy of pharmacologic options for the management of patients with T2DM and obesity, such as incretins; Develop individualised therapeutic goals and strategies to improve outcomes for patients with T2DM and obesity.

Visit https://www.peervoice.com/USX860 to view the entire programme with slides. After completing “Personalising Care Across the Disease Continuum: From Prediabetes Through Type 2 Diabetes”, participants will be able to: Discuss current recommendations for glucose-lowering in patients with prediabetes or type 2 diabetes (T2DM); Formulate individualised treatment plans based upon current guideline recommendations for patients with newly diagnosed prediabetes or T2DM; Identify patients with prediabetes or T2DM who may benefit from treatment intensification.

Visit https://www.peervoice.com/BFW860 to view the entire programme with slides. After completing “Evaluating the Evidence for SGLT2 Inhibition in CKD: Highlights From the 2021 Virtual ERA-EDTA Congress”, participants will be able to: Describe key safety and efficacy data on SGLT2 inhibition for the management of chronic kidney disease (CKD); Summarise what the latest data on SGLT2 inhibition add to the current treatment algorithm for CKD; Discuss the clinical implications of SGLT2 inhibition in the context of managing patients with CKD.